<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Moreno T</submitter><funding>Cancer Research UK</funding><funding>European Research Council</funding><funding>Medical Research Council</funding><funding>The Francis Crick Institute</funding><funding>Wellcome Trust</funding><pagination>2923-2935</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7610680</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>40(16)</volume><pubmed_abstract>The survival rate in lung cancer remains stubbornly low and there is an urgent need for the identification of new therapeutic targets. In the last decade, several members of the SWI/SNF chromatin remodeling complexes have been described altered in different tumor types. Nevertheless, the precise mechanisms of their impact on cancer progression, as well as the application of this knowledge to cancer patient management are largely unknown. In this study, we performed targeted sequencing of a cohort of lung cancer patients on genes involved in chromatin structure. In addition, we studied at the protein level the expression of these genes in cancer samples and performed functional experiments to identify the molecular mechanisms linking alterations of chromatin remodeling genes and tumor devel</pubmed_abstract><journal>Oncogene</journal><pubmed_title>ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer.</pubmed_title><pmcid>PMC7610680</pmcid><funding_grant_id>10152</funding_grant_id><funding_grant_id>FC001152</funding_grant_id><funding_grant_id>637904</funding_grant_id><pubmed_authors>Agraz-Doblas A</pubmed_authors><pubmed_authors>Cereceda L</pubmed_authors><pubmed_authors>Casar B</pubmed_authors><pubmed_authors>Freire J</pubmed_authors><pubmed_authors>Astudillo A</pubmed_authors><pubmed_authors>Blanco R</pubmed_authors><pubmed_authors>Quevedo L</pubmed_authors><pubmed_authors>Gomez-Roman J</pubmed_authors><pubmed_authors>Revilla C</pubmed_authors><pubmed_authors>Montes-Moreno S</pubmed_authors><pubmed_authors>Gonzalez-Silva L</pubmed_authors><pubmed_authors>Moreno T</pubmed_authors><pubmed_authors>Scaffidi P</pubmed_authors><pubmed_authors>Isidro P</pubmed_authors><pubmed_authors>Varela I</pubmed_authors><pubmed_authors>Betancor-Fernandez I</pubmed_authors><pubmed_authors>Crespo P</pubmed_authors><pubmed_authors>Morales Torres C</pubmed_authors><pubmed_authors>Salido E</pubmed_authors><pubmed_authors>Monterde B</pubmed_authors></additional><is_claimable>false</is_claimable><name>ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer.</name><description>The survival rate in lung cancer remains stubbornly low and there is an urgent need for the identification of new therapeutic targets. In the last decade, several members of the SWI/SNF chromatin remodeling complexes have been described altered in different tumor types. Nevertheless, the precise mechanisms of their impact on cancer progression, as well as the application of this knowledge to cancer patient management are largely unknown. In this study, we performed targeted sequencing of a cohort of lung cancer patients on genes involved in chromatin structure. In addition, we studied at the protein level the expression of these genes in cancer samples and performed functional experiments to identify the molecular mechanisms linking alterations of chromatin remodeling genes and tumor devel</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2026-05-07T22:42:32.606Z</modification><creation>2022-02-09T15:50:23.944Z</creation></dates><accession>S-EPMC7610680</accession><cross_references><pubmed>33742126</pubmed><doi>10.1038/s41388-021-01748-y</doi></cross_references></HashMap>